OnkoBank: A clinically annotated cancer biobank supporting translational and precision oncology research.

Abstract

e15190 Background: High-quality, clinically annotated biobanks are essential infrastructure for translational cancer research and biomarker discovery. OnkoBank was established as a centralized, multi-institutional initiative to systematically collect biological specimens from patients with malignant disease and non-malignant controls, together with standardized clinical and pathological data. We present a descriptive analysis of the current OnkoBank cohort, focusing on tumor anatomical distribution and histopathological characteristics. Methods: This analysis included samples from 2,268 patients enrolled in OnkoBank. Collected biospecimens comprised fresh-frozen tumor tissue, fresh-frozen non-malignant control tissue, and blood-derived samples. Histopathological diagnoses were established for each sample by board-certified pathologists. Clinical and pathological variables were recorded in pseudonymized form using a REDCap-based data management system. Descriptive statistics were used to summarize tumor localization, histological categories, disease stage, and sample availability. Results: Among the 2,268 registered patients, tumors most frequently originated from the central nervous system (25.7%), melanoma or other skin tumors (18.8%), kidney (8.8%), colorectum (7.8%), and uterine corpus (7.6%), followed by ovarian (5.9%), pancreatic (3.0%), prostate (2.5%), bladder (2.2%), and breast cancers (1.8%). Less frequent tumor types included cervical (1.3%), liver (1.1%), vulvar (1.0%), and other localizations (9.1%), demonstrating broad representation across malignant diseases. Pathological tumor stage is reported in 45.6% of cases, with pT1–pT3 disease accounting for most staged tumors (pT1 14.8%, pT2 9.9%, pT3 15.9%), while pT4 disease is less common (3.1%). Distant metastatic disease is infrequent, with metastases present in 1.4% of patients, absent in 67.1%, and identified synchronously with the primary tumor in 24.7% of cases with available data. Paired tumor–normal specimens are available in 43.6% of cases, enabling matched molecular analyses. Conclusions: OnkoBank represents a large, uniformly annotated cancer biobank with comprehensive histopathological coverage and broad tumor-type representation. The availability of high-quality biospecimens, paired tumor–normal samples, and standardized clinical data provides a robust platform for large-scale translational research, biomarker discovery, and precision oncology studies.